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Abstract
Background: Exercise may improve clinical and quality of life outcomes for men
with prostate cancer. No randomized controlled trials (RCTs) have examined the
feasibility, safety, and acceptability of remote exercise training in men with metastatic castrate-resistant prostate cancer (mCRPC).
Methods: We conducted a pilot RCT (1:1:1 aerobic or resistance exercise 3x/
week or usual care) to determine the feasibility, safety, and acceptability of remotely monitored exercise over 12 weeks in 25 men with mCRPC. A prescribed
exercise program was based on baseline testing including high- and moderate-
intensity aerobic exercise or resistance exercise completed at a local exercise facility. Feasibility was based on attendance, adherence, and tolerance; safety on
adverse events; and acceptability on participant interviews.
Results: Between March 2016 and March 2020, 25 patients were randomized
(8 aerobic, 7 resistance, and 10 control). Twenty-three men (82%) completed the
12-week study. Men who completed the remote intervention attempted 90% and
96% of prescribed aerobic and resistance training sessions, respectively, and 86%
and 88% of attempted sessions were completed as or more than prescribed. We
observed changes in performance tests that corresponded with the exercise prescription. No safety concerns were identified. Ninety percent of participants interviewed were satisfied with the program and would recommend it to others.
Conclusions: Remotely monitored exercise training is feasible, safe, and acceptable in men with mCRPC; there was no difference in these outcomes by mode

This is an open access article under the terms of the Creative Commons Attribution License, which permits use, distribution and reproduction in any medium, provided
the original work is properly cited.
© 2021 The Authors. Cancer Medicine published by John Wiley & Sons Ltd.
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of exercise. Through this research, we provide direction and rationale for future
studies of exercise and clinical outcomes in patients with metastatic prostate
cancer.
KEYWORDS

behavioral intervention, physical activity, remote, strength training
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I N T RO DU CT ION

Prostate cancer (PC) remains the second leading cause of
cancer death among men in the United States (US)1 and
the fifth leading cause of death among men worldwide.2
Significant advances have been made in therapies for advanced PC3; median survival is approximately 32 months
for metastatic castrate-resistant PC (mCRPC).4 However,
these therapies have severe cardiovascular and metabolic
effects; negatively impact cognitive, psychological, muscle, and bone health; and may lead to decreased cardiorespiratory fitness, frailty, and reduced quality of life (QOL).5
Adjuvant interventions, such as exercise, have promise for
preventing or reducing detrimental side effects of therapy
for advanced PC and warrant further examination in men
with mCRPC.
The effects of aerobic and resistance exercise in men
with PC have been examined in multiple randomized controlled trials (RCTs), evaluated in systematic reviews,6,7
and reported that exercise interventions can improve the
quality of life (including fatigue), fitness, and function
for men with PC. For example, one study in men undergoing androgen deprivation therapy (ADT) reported that
an onsite supervised multimodal (aerobic and resistance
training) program significantly improved muscle mass,
physical strength, walk times, and general health, and
also reduced fatigue.8 Few studies have been completed
in men with metastatic PC due to perceived elevated risk
of skeletal-related events. In a 12-week RCT of onsite supervised resistance exercise (2/week) among 20 men with
bone metastases, 75% completed the study. No adverse
events or skeletal complications occurred during exercise,
and attendance, exercise tolerance, and rated perceived exertion (RPE) were high.9 In a 12-week efficacy and safety
study of 57 PC patients with bone metastasis randomized
to multimodal supervised exercise (3x/week) versus control, attendance, tolerance, and RPE were similar to the
study by Cormie et al.9 and exercise increased self-reported
physical functioning and objectively measured lower body
muscle strength, with no differences in adverse events or
skeletal fractures.10 Notably, these studies focused on men
with bone metastases and tested the safety and feasibility
of onsite supervised exercise.
The feasibility, safety, and effects of remote-based
aerobic or resistance exercise in men with metastatic

castrate-resistant prostate cancer (mCRPC) are unknown.
Thus, we conducted the CHAMP study (A Clinical trial
of High-intensity Aerobic and resistance exercise for
Metastatic Prostate cancer) and report here on the primary (feasibility, safety, and acceptability) and secondary
(cardiovascular fitness, strength, and Halabi prognostic
score) outcomes.11
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MATERIALS AND METHO D S

2.1 | Study design, recruitment, and
eligibility
CHAMP was a three-arm 12-week pilot RCT among men
with mCRPC. Main inclusion criteria included: histologically confirmed PC and clinically confirmed castration
resistance; Eastern Cooperative Oncology Group (ECOG)
performance status of 0–1; clearance to undergo a maximal
steep ramp exercise test on a cycle ergometer and complete vigorous aerobic and resistance exercise training;
and English proficiency. Main exclusion criteria included:
contraindications to exercise (e.g., serious cardiovascular
event within 12 months); poorly controlled hypertension;
spinal cord compromise; moderate-to-severe bone pain;
self-reported ≥75 min/week of vigorous aerobic exercise;
or ≥3 days/week of structured resistance exercise (see File
S1 for all criteria). Patients reporting chest pain, medically
supervised activity, or shortness of breath performing
activities of daily living required cardiologist clearance.
Pre-CRPC chemotherapy was allowed; post-CRPC chemotherapy was allowed with physician approval. Men were
allowed to have past or current treatment with abiraterone or enzalutamide. All participants were required to be
on ADT during the study period. Written informed consent was obtained before all study assessments. Ethics
approval was obtained at the University of California,
San Francisco (UCSF). This study was registered at
ClinicalTrials.gov (Identifier NCT 02613273).
Participants were recruited from patient lists and physician referrals, with a focus on those living within 3 h drive
of UCSF. The study protocol designed in 2016 specified
onsite supervised exercise 3/week at the UCSF Mission
Bay campus, but travel presented a barrier to accrual. The
protocol was updated in 2017 to offer onsite supervised or
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remotely monitored programs. Because of the popularity
of the remote option, only the remote option was offered
from 2018 to 2020. The pilot study was planned to enroll
39 participants; however, investigators decided to end enrollment in March 2020 due to the COVID-19 pandemic
and the closure of gyms. Three participants were assigned
to the onsite supervised program (2 aerobic, 1 resistance;
2 completed, one moved out of state after randomization)
and 15 participants were assigned to the remotely monitored program (8 aerobic, 7 resistance; all 15 (100%) completed). Due to low enrollment in the supervised mode
and the novelty of the remote strategy, the remote participants are the focus of this paper.

2.2 | Randomization, stratification, and
allocation concealment
Following completion of screening, consent, and baseline procedures, men were randomized 1:1:1 to aerobic
exercise, resistance exercise, or usual care with block
sizes of 1–2 using the R package blockrand (https://
cran.r-project.org/web/packages/blockrand/blockrand.
pdf). Patients were stratified based on active therapy (abiraterone, enzalutamide, chemotherapy, etc.) at the time
of enrollment (yes/no). Allocation sequences were uploaded to Research Electronic Data Capture (REDCap)12
and schema was concealed from the coordinator assigning participants.

2.3 | Remote exercise program
implementation
All men completed their exercise prescription at an exercise facility near their residence and visited UCSF at baseline and 12 weeks. We provided a “concierge service” to
identify suitable gyms. We confirmed an employee was
present most of the time and the gym was open at least
3 days per week, verified specific equipment to perform
the exercises, and confirmed whether a gym waiver was
signed and the amount of the monthly fees. Gym staff/
trainers were not part of the study and did not work with
participants; however, we verified that if the patient had
a question with a particular piece of equipment, for instance, the staff would be available to help. The gym
personnel activating the membership knew that the participant was part of a research study. The study paid for
a 3-month membership. We asked men to exercise at a
gym to ensure that they had access to suitable equipment
for the resistance training and gym staff to reduce safety
concerns, given all men had mCRPC. All men were asked
to exercise 3 days a week (weekends allowed) with at least
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a day of rest in between; participants separated sessions by
24–48 h of rest between training the same muscle groups.
In addition, the participants were counseled to follow
their prescription, not to do anything else new, and not to
ask gym staff for additional exercises.
During the baseline visit, intervention participants
received a Polar HR strap (H10) and were remotely monitored multiple times weekly by the exercise physiologist (EP) through Polar accounts using study-generated
email addresses. Participants set up the Polar Beat app
on their smartphone using the study account (N = 14) or
manually tracked Polar heart rate data using paper logs
(N = 1). Before each prescribed exercise session, participants completed an online survey, reporting hours
of sleep the night prior, resting heart rate, bone pain,
fatigue, mood, motivation, and muscle soreness. They
completed a post-exercise survey assessing total adherence versus modifications to prescribed workouts (more
or less sets, reps and/or weight); session RPE; session tolerance; and mood.
Participants were instructed to wear the HR monitor
for all prescribed sessions. Pre- and post-exercise session
surveys were reviewed daily by the EP for compliance and
adverse events (AEs). Weekly check-ins were scheduled
for Thursday or Friday via email or phone, with additional
calls if concerns requiring more communication were
observed.

2.4

|

Control arm

The control arm received usual standard of care from baseline to 12 weeks. At 12 weeks, they received their choice
of an aerobic or resistance exercise program, personalized
based on their 12-week testing data, and their exercise test
summary results (baseline and post-control period test).
All arms received diet and exercise booklets, psychosocial support material, and a $50 gift card after the 12 weeks
of intervention.

2.5

|

Exercise programs

The aerobic exercise intervention aimed to meet the
American College of Sports Medicine (ACSM) guidelines of at least 20–3 0 min of moderate-t o-v igorous
intensity exercise 3–5 days/week. 13 Exercise prescriptions were tailored to each participant's baseline cardiorespiratory and strength assessments and
consultation with the treating medical physicians
(e.g., reducing weight-b earing resistance exercises if
the patient had bone metastasis as a safety modification) (File S2). The aerobic training prescription, all
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completed on a cycle ergometer, was based on results
of a baseline maximal steep ramp test. 14 The program
was designed to be vigorous and included 2 days of
high-i ntensity interval training (HIIT) sessions and
1 day of a moderate-i ntensity continuous exercise
session to balance out exertion levels and provide
enough rest and recovery, given the age and limitations of the study population. The resistance training
prescription was established on baseline 1-r epetition
maximum (1-R M) tests. Training sessions progressed
from 1 to 4 sets of 4–1 5 repetitions. Exercise selection
was modified in consultation with the EP throughout
the program in response to participant feedback (e.g.,
tolerability, bone pain, etc.).

2.6

|

Data collection

Primary outcomes were intervention feasibility (attendance, adherence to the exercise prescription, and tolerance), safety (adverse events [AEs]), and acceptability
(assessed via interview). Attendance equals the number
of exercise sessions attended out of 36 planned sessions.
Adherence equals the number of sessions completed
as or more than prescribed out of 36 planned sessions.
Adherence to the prescription was assessed by the EP
reviewing the HR data in the Polar accounts each week.
Based on meeting HR targets and session durations, the
EP recorded whether they adhered or not to the prescription (yes/no) and if not, did more or less as prescribed
(more time/exceed heart rate or less time/did not hit
heart rate). For resistance exercise, to reduce participant
burden we did not require the participants to record the
exact sets x reps x load on the sessional surveys, but to
indicate if they did more or less of the prescribed exercise,
and if yes, then indicate whether they did more or less
sets, reps, and weight. The EP discussed the surveys and
Polar data with the participant on weekly calls and made
a final adherence assessment. Tolerance was measured at
each post-training survey (0–10 scale: 0 = intolerable and
10 = highly tolerable).
Secondary outcomes included fatigue and bone pain
measured using visual analog scales at each exercise session, number of participants reporting use of opiate pain
medication, and changes in physical function and strength,
which were measured at baseline and 12-week study visits. QOL was also a secondary outcome but not the focus
of this paper. Timed fitness measurements included stair
climb, 400-m walk, and repeated sit-to-stand.15,16 For resistance testing and initial training, 1-RM tests included
the following exercises: chest press, leg press or extension,
and seated row.

Research blood and urine and standard of care blood
measurements were also collected, and participants completed surveys on lifestyle, diet, and QOL.12 Exploratory
outcomes included the Halabi nomogram score (prognostic model for overall survival in mCRPC patients) and its
components,11 median progression-free survival, median
overall survival, and median time to first occurrence of
symptomatic skeletal-related events.
A post-study remote exercise feedback interview was
added to the protocol in December 2019 and completed by
67% (n = 10) of remote intervention participants (5 aerobic; 5 resistance). The median time from the end of study
to interview was 6 months (IQR 4.8, 13.8).

|

2.7

Statistical analysis

The main study results (except for our enrollment summary and CONSORT Figure 1) are presented for the
remote exercise intervention and control patients only
(N = 25). Patients’ demographics and clinical characteristics were described using medians and interquartile ranges (IQR) for continuous variables and N with
percentage for categorical variables. We used descriptive statistics to summarize results from the feedback.
To assess preliminary efficacy of the interventions,
absolute change from baseline to 12 weeks for the exercise tests, and Halabi score and its blood-related
components were compared between groups (aerobic
vs. control, resistance vs. control and aerobic vs. resistance) using the Wilcoxon rank-sum tests. Statistical
analyses were performed using SAS version 9.4 and R
version 4.0.3.

3
3.1

|

RESULTS

|

Enrollment and follow-up

Following ethics approval at UCSF, 510 men were assessed for eligibility between 4 March, 2016 and 20 March,
2020. Recruitment and loss to follow-up are detailed in
Figure 1. Thirty-five percent (n = 177) were excluded
due to having PC disease states other than mCRPC, while
17% (n = 88) were excluded due to provider's discretion
(e.g., comorbidities, new heart conditions, progression
of disease, and potential for noncompliance). Five percent (n = 28) of those screened were consented and randomized. Eighty-two percent of randomized participants
(n = 23) completed the study (Figure 1). Eighty-six percent of randomized participants (n = 24) completed baseline and 12-week surveys.
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Assessed for eligibility

(n=510)

|

5

Excluded (n=482)
Not meeting inclusion criteria
or meeting exclusion criteria
(n=388)*

•
•
•
•
•

Declined participation (n=29)
Not meeting fitness inclusion
criteria (n=30)
Unable to contact after 3 times
(n=30)
Cardiologist clearance not
returned or declined (n=5)

Randomized (n=28)

Aerobic intervention Arm (n=10)
Received aerobic allocation (n=9, 8
remote, 1 supervised)
1 withdrew due to noncompliance

•

•
did not receive allocation
• 1(moved
out of state after

Resistance intervention Arm
(n=8)
Received resistance
allocation (n=8, 7 remote,
1 supervised)

Control Arm (n=10)
Received control
allocation (n=10)

Completed 12-week visit (n=7)
1 did not complete (based
on medical advice)

Completed 12-week visit (n=8)
2 declined (disliked
testing, other
commitments)

•

•

randomization)

Completed 12-week visit (n=8)

•

•

*177 were excluded due to having PC disease states other than mCRPC; 88 were excluded due to provider’s discretion (e.g.,
comorbidities, new heart conditions, progression of disease, potential for noncompliance); 123 were excluded due to not meeting
other eligibility criteria (see Supporting File 1).

FIGURE 1

CONSORT diagram of recruitment and loss to follow-up during the trial

3.2 | Participant demographics for the
remote intervention patient and control
groups (N = 25)
Median age of participants was 71 years (range = 51–84).
Median BMI was 28.7 kg/m2 (range = 22.6–36.7); 36%
were obese (Table 1). Twenty percent self-identified in a
racial/ethnic minority group. Eighty-four percent had a

4-year university education or higher. Eighty-four percent
were married or in a civil partnership. Median distance
from their residence to UCSF was 68 miles.
Median time from diagnosis to enrollment was
10.5 years (range = 0.9–26.3). Radiation therapy (80%)
was the most common localized treatment. Fifty-six percent were prescribed abiraterone, 28% enzalutamide, 92%
received other antiandrogen therapy, 48% were prescribed

6
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TABLE 1
(IQR)

Baseline characteristics of randomized remote aerobic and resistance exercise and control study participants, n (%) or median
Remote aerobic
(n = 8)

Remote resistance
(n = 7)

Control
(n = 10)

Overall
(n = 25)

70 (68, 72)

73 (70, 78)

72 (66, 79)

71 (67, 75)

White

6 (75)

5 (71)

8 (80)

19 (76)

African American/Black

1 (13)

1 (14)

1 (10)

3 (12)

Demographics
Age, years
Race

Asian

1 (13)

0 (0)

0 (0)

1 (4)

Other

0 (0)

1 (14)

0 (0)

1 (4)

Declined to answer

0 (0)

0 (0)

1 (10)

1 (4)

1 (13)

1 (14)

0 (0)

2 (8)

Education
High school or less
2-year college

2 (25)

0 (0)

0 (0)

2 (8)

4-year college

1 (13)

2 (29)

5 (50)

8 (32)

Grad./prof. school

4 (50)

4 (57)

5 (50)

13 (52)

Full-time

0 (0)

1 (14)

1 (10)

2 (8)

Part-time

1 (13)

1 (14)

1 (10)

3 (12)

Employment status

Retired

6 (75)

5 (71)

7 (70)

18 (72)

Other

1 (13)

0 (0)

1 (10)

2 (8)

Married/civil partnership

8 (100)

6 (86)

8 (80)

22 (88)

Single/divorced/widowed

0 (0)

1 (14)

2 (20)

3 (12)

76 (27, 98)

92 (73, 231)

23 (4, 45)

68 (15, 92)

Relationship status

Distance from study site, km
Anthropometrics
Body mass index, kg/m2

31 (28, 32)

30 (26, 32)

27 (26, 29)

29 (26, 32)

Waist circumference, cm

106 (99, 112)

103 (88, 106)

103 (93, 109)

104 (94,
109)

Waist-to-hip ratio

1.03 (0.94, 1.04)

0.98 (0.94, 1.00)

1.02 (0.96, 1.04)

1.00 (0.96,
1.04)

9.6 (1.7, 13.5)

12.6 (1.9, 12.8)

7.7 (4.9, 18.0)

10.5 (4.2,
14.3)

3 (38)

1 (14)

4 (40)

8 (32)

Clinical
Time since diagnosis, year
Comorbiditiesa,b
Hypertension
Hypercholesteremia

3 (38)

4 (57)

3 (30)

10 (40)

Cardiovascular disease

2 (25)

2 (29)

1 (10)

5 (20)

Diabetes type II

1 (13)

0 (0)

0 (0)

1 (4)

Osteoporosis

0 (0)

1 (14)

0 (0)

1 (4)

Osteoarthritis

1 (13)

2 (29)

1 (10)

4 (16)

Stomach/intestinal diseasec

1 (13)

3 (43)

3 (30)

7 (28)

Depression

0 (0)

3 (43)

1 (10)

4 (16)

Anemia

1 (13)

1 (14)

2 (20)

4 (16)

Other cancer

1 (13)

0 (0)

2 (20)

3 (12)
(Continues)
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(Continued)
Remote aerobic
(n = 8)

Remote resistance
(n = 7)

Control
(n = 10)

Overall
(n = 25)

PSA level at diagnosis, ng/mL

14.2 (6.9, 120.0)

6.0 (4.4, 28.9)

11.1 (9.5, 20.9)

10.0 (5.4,
21.2)

PSA level at enrollment, ng/mLb

2.5 (0.7, 20.3)

3.5 (1.0, 7.9)

10.2 (1.9, 38.0)

3.9 (1.1,
16.4)

4 (50)

4 (57)

6 (60)

14 (56)

Gleason grade
2–6
3+4

1 (13)

1 (14)

3 (30)

5 (20)

4+3

1 (13)

2 (29)

0 (0)

3 (12)

2 (25)

0 (0)

1 (10)

3 (12)

Radical prostatectomy

3 (38)

5 (71)

5 (50)

13 (52)

Radiation therapy

6 (75)

6 (86)

8 (80)

20 (80)

6 (75)

4 (57)

4 (40)

14 (56)

8–10
Local therapies

a,d

Metastasis at enrollmentb
Lymph node(s)
Bone

6 (75)

5 (71)

7 (70)

18 (72)

Lung

0 (0)

0 (0)

1 (10)

1 (4)

Systemic therapiesa,d
LHRH analog/antagonist

8 (100)

7 (100)

10 (100)

25 (100)

Abirateronee

6 (75)

3 (43)

5 (50)

14 (56)

Enzalutamidee

2 (25)

2 (29)

3 (30)

7 (28)

Other antiandrogen

8 (100)

5 (71)

10 (100)

23 (92)

Chemotherapy

2 (25)

1 (14)

2 (20)

5 (20)

Sipuleucel-T

3 (38)

4 (57)

5 (50)

12 (48)

Other immunotherapy

0 (0)

1 (14)

0 (0)

1 (4)

Radium-223

1 (13)

0 (0)

1 (10)

2 (8)

5 (63)

5 (71)

8 (80)

18 (72)

Halabi nomogram score
Low
Intermediate

3 (38)

2 (29)

1 (10)

6 (24)

High

0 (0)

0 (0)

1 (10)

1 (4)

0 (0)

1 (14)

1 (10)

2 (8)

Lifestyle characteristics
Smoking status
Current
Former

3 (38)

2 (29)

4 (40)

9 (36)

Never

5 (63)

4 (57)

5 (50)

14 (56)

163 (75, 263)

90 (0, 140)

120 (20, 180)

120 (60,
175)

Light exercise, min/week
Moderate exercise, min/week

54 (0, 130)

0 (0, 120)

55 (0, 150)

30 (0, 120)

Vigorous exercise, min/week

0 (0, 0)

0 (0, 0)

0 (0, 0)

0 (0, 0)

Resistance exercise, min/week

0 (0, 15)

0 (0, 0)

0 (0, 0)

0 (0, 0)

Abbreviations: IQR, interquartile range; PSA, prostate-specific antigen.
a

Categories are not mutually exclusive.

b

Reported by patient at time of enrollment. Reported hypertension, hypercholesterolemia, cardiovascular disease, type 2 diabetes, and osteoporosis. Other
comorbidities comprising ≥10% of total population were included in table.

c

Stomach or intestinal diseases (e.g., acid reflux, hepatitis C, gallstones, pancreatitis, irritable bowel syndrome, and ulcer disease).

d

From the medical record at time of enrollment.

e

Eighty-six percent of those receiving abiraterone and 86% of those receiving enzalutamide were taking this drug at baseline.

7
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Sipuleucel-T, and 20% were treated with chemotherapy
before the study. Seventy-two percent had a low Halabi
nomogram score. Most men did no vigorous or resistance
exercise at enrollment, and did a median of 30 min/week
of moderate exercise. Eight percent were current smokers
and 36% were past smokers.

3.3 | Feasibility of remote
exercise program
Remote intervention participants attempted 93% of prescribed workouts (Table 2). Pre–post-exercise session
survey completion rate was 92% for the resistance arm
and 94% for the aerobic arm. Of sessions attempted,
87% were self-reported as having been completed as
prescribed or with more sets, reps, and/or weight (88%
resistance remote and 86% aerobic remote). Median tolerance across all sessions was 6 (IQR = 5, 7). Subjects
found the resistance exercises (median = 7) more tolerable than the aerobic arm (median = 5). Men in both
arms reported no bone pain and low fatigue levels during exercise, with the aerobic arm reporting slightly
more fatigue (median = 4) than the resistance arm (median = 3). Median RPE was 6 (0–10 scale, 5 = moderate,
6 = hard, 8 = very hard), combined (IQR = 6, 8) and
separately for the exercise arms.

N (%) or median (IQR)

Aerobic
(n = 8)

No safety concerns related to the exercise programs were
identified. Eight of 14 AEs were reported by men in the resistance arm (Table 3) and were most commonly joint or
bone pain consistent with disease status. Three joint/bone
pain AEs were classified as possibly related to the study.
One man in the aerobic arm experienced hip and lower back
pain, while two men in the resistance arm reported pain,
one in the heel and the other in the shoulder where he had
received radiation therapy >1 year prior to enrollment. The
first and third patients received pain medication, and the
second patient's pain resolved after a physician visit.

3.5 | Intervention interview results and
study acceptability
Patients reported high overall satisfaction with the program, 90% being satisfied or very satisfied, 90% rating the
program as very good or excellent, and 90% reporting they
would recommend the study to others. Notably, 90% of
participants reporting they would not have participated if
the program was only available onsite (these participants
completed the study prior to the COVID-19 pandemic).
Average one-way transportation time was 10 min to their
local study gym and 158 min to UCSF.

Resistance
(n = 7)

1

1

7 (88)

7 (100)

Number of sessions attended (of 36 sessions)

34 (33, 35)

35 (35, 35)

Number who completed ≥70% exercise sessions as
or more than prescribedb

5 (63)

7 (100)

Number of sessions completed as or more than
prescribed (of 36 sessions)

32 (22, 34)

30 (29, 33)

Median sessional tolerancec

5 (4, 7)

7 (5, 8)

Number who completed ≥70% exercise sessions
with tolerance ≥5b

6 (75)

6 (86)

Perceived exercise intensity (session RPE)d

6 (5, 8)

6 (5, 7)

Perceived bone pain levele

0 (0, 1)

0 (0, 1)

4 (2, 5)

3 (2, 5)

Abbreviations: IQR, interquartile range; RPE, rated perceived exertion.
a

Calculated out of 36 sessions.
Calculated out of sessions completed.

Scale 0–10: 0 = not tolerable, 5 = moderately tolerable, 10 = very tolerable.

d

Scale 0–10: 0 = no exertion, 5 = moderate exertion, 10 = high exertion.

e

Scale 0–10: 0 = no bone pain, 5 = moderate bone pain, 10 = high bone pain.

f

Adverse events

Attendance at ≥70% of exercise sessionsa

Perceived fatigue level

c

|

Dropout

f

b

3.4

Scale 0–10: 0 = no fatigue, 5 = moderate fatigue, 10 = high fatigue.

T A B L E 2 Safety and feasibility of
remote aerobic and resistance exercise
among men with mCRPC
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T A B L E 3 Adverse events among men
with mCRPC participating in a 12-week
trial of remote aerobic or resistance
exercise or control

|

Aerobic
(n = 8)

Resistance
(n = 7)

Control
(n = 10)

Overall
(n = 25)

Any AE

4

8

2

14

Study-related AE

1

2

0

3

Joint or bone pain, any

1

6

1

8

Joint or bone pain, study-related

1

2

0

3

Muscle pain/injury, anya

2

1

0

3

0

1

0

1

9

Specific AEs

Dizziness or vertigo, any

a
a

0

0

1

1

Other (cataract issue), anya

1

0

0

1

Cardiovascular event, any
a

No AE’s in this category were study-related.

Using the HR monitors did not pose significant issues,
and no one reported difficulty with completing the online surveys. However, technology literacy in the enrolled
study population was high. All participants owned a computer, 70% had owned a tablet for 10 years, and 100% had
owned a smartphone for an average of 13 years (Table 4).
Most participants found the short, weekly calls with
exercise specialists helpful. Participants remembered to
exercise, found time to exercise, found an appropriate
place to do the prescribed exercise(s), and remembered to
use the HR monitor when exercising, while completing
the exercises was considered more difficult. Participant
feedback and suggestions for next steps are summarized
in File S3.

3.6
3.6.1

|

Secondary outcomes

|

Exercise testing results

Both the aerobic and resistance arms showed mode-
specific adaptations (File S4).
The resistance arm improved more in the 1-RM tests
than the other two arms, while the aerobic arm had greater
changes in the steep ramp test performed on the bike and
the 400-m walk test than the other two arms. Resting heart
rate was modestly reduced in the resistance and aerobic
arms and modestly increased in the control arm. For additional testing parameters, see File S4.

3.6.2

|

Halabi score outcomes

There were no meaningful changes in absolute Halabi
scores, within or between arms; and no differences in predicted 24, 36, 48-month survival probabilities across arms
(data not shown). Changes in the Halabi score components are summarized in File S5, showing 30%, 29%, and

0% of participants increasing from a lower to higher Halabi
score level (poorer prognosis) for the control, resistance,
and aerobic exercise arms, respectively, primarily driven
by diagnosis of a new metastasis, change in ECOG status,
and change in lactate dehydrogenase.

4

|

DISC USSION

In this pilot RCT, we found that remote exercise was feasible, safe, and acceptable for men with mCRPC. The primary strength of the remote program was convenience,
and the remote exercise program attendance rate was
high, with a high satisfaction rate. In addition, the RPE
of the exercise sessions showed that the participants were
being adequately challenged (median = 6). Reported bone
pain was none to low, with a median of 0 out of 10 overall,
demonstrating that the program was successful in creating a tailored program that avoided patients’ metastatic
sites to prevent injury. Three moderate AEs were possibly
related to the study, but were more likely related to natural disease progression.
The 12-week exercise programs resulted in expected
improvements. Aerobic training improved cardiorespiratory performance and resistance training was superior for
improving strength and function. As anticipated, involvement in a structured program led to routine exercise and
over 90% of the workouts were attempted.
We acknowledge that many men screened out due to
the provider's discretion (including having comorbidities
or disease progression) or eligibility criteria. Since starting the study, a global phase III study called INTERVAL-
GAP4 (INTense exeRcise for surviVAL among men with
Metastatic Prostate Cancer) was launched to study the
effect of 48 weeks of supervised aerobic and resistance
exercise followed by 48 weeks of self-managed exercise
on overall and progression-free survival among 866 men
with mCRPC or metastatic hormone-sensitive prostate

10
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TABLE 4

Acceptability of remote program
Aerobic
(n = 5)

Resistance
(n = 5)

Overall
(n = 10)

Characteristic, median (IQR), or n (%)
Setup
Usefulness of orientationa

4 (4, 5)

5 (4, 5)

5 (4, 5)

Problems setting up exercise facility/gym

0 (0%)

2 (40%)

2 (20%)

Challenges with setup of Polar heart rate monitor to
smartphone

1 (20%)

1 (20%)

2 (20%)

Usefulness of exercise record sheeta

4 (4, 4)

4 (4, 5)

4 (4, 5)

Difficulty recording exercise on record sheet

1 (20%)

0 (0%)

1 (10%)

Usefulness of resistance exercise picture guidea,b

N/A

5 (4, 5)

N/A

Usefulness of Polar heart rate monitor

5 (4, 5)

5 (4, 5)

4 (3, 5)

Always or almost always wore heart rate monitor during your
exercise program

5 (100%)

5 (100%)

10 (100%)

Difficulty using heart rate monitor

0 (0%)

2 (40%)

2 (20%)

Comfort of chest strap

4 (3, 4)

3 (3, 4)

4 (3, 4)

Convenience of chest strapd

4 (4, 4)

4 (4, 4)

4 (4, 4)

0 (0%)

0 (0%)

0 (0%)

4 (4, 4)

5 (5, 5)

5 (4, 5)

0 (0%)

0 (%)

0 (0%)

Components, usefulness, and difficulty

c

Difficulty completing pre- and post-exercise session surveys
a

Usefulness of weekly calls with exercise specialist
Frequency of weekly calls was:
Too little
Just right

4 (80%)

5 (100%)

9 (90%)

Too much

1 (20%)

0 (0%)

1 (10%)

6 (5, 15)

5 (3, 15)

6 (5, 15)

5 (100%)

5 (100%)

10 (100%)

Felt exercise specialist answered all questions

4 (80%)

5 (100%)

9 (90%)

Called exercise specialist outside of scheduled weekly call

1 (20%)

2 (40%)

3 (30%)

Duration of weekly call (min)
The length of the call was:e
Just right

a

Usefulness of the local gym

4 (4, 4)

4 (3, 4)

4 (3, 4)

Obstacles attending local gym

0 (0%)

1 (20%)

1 (10%)

Preferred workout time, AM

3 (60%)

2 (40%)

5 (50%)

Preferred workout time, PM

2 (40%)

3 (60%)

5 (50%)

Ease of attending remote sessions 3x/weekf

4 (3, 4)

4 (4, 4)

4 (3, 4)

2 (2, 2)

3 (2, 3)

2 (2, 3)

2 (2, 2)

3 (2, 3)

2 (2, 3)

Choose other exercises to do beyond those assigned

N/A

4 (4, 4)

N/A

Remember how to do the exercises correctlyg

4 (2, 4)

4 (3, 4)

4 (3, 4)

g

Remember to exercise

5 (5, 5)

5 (4, 5)

5 (5, 5)

g

Find time to exercise

4 (3, 5)

5 (4, 5)

5 (3, 5)

Find an appropriate place to do the prescribed exercise(s)g

5 (4, 5)

5 (4, 5)

5 (4, 5)

5 (4, 5)

5 (3, 5)

5 (3, 5)

Remember why exercise matters

5 (5, 5)

5 (5, 5)

5 (5, 5)

Remember to use the heart rate monitor when you exercisedg

5 (5, 5)

5 (5, 5)

5 (5, 5)

f

Ease of exercise program
How easy was it to

Complete exercises prepared by exercise specialistg
b,g

g

Stay motivated

g

(Continues)
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(Continued)

Would be able to attend exercise sessions onsite three times a
week at UCSF (if no opportunity for remote program)

Aerobic
(n = 5)

Resistance
(n = 5)

Overall
(n = 10)

1 (20%)

0 (0%)

1 (10%)

Overall program rating
Excellent

3 (60%)

2 (40%)

5 (50%)

Very good

1 (20%)

3 (60%)

4 (40%)

Good

0 (0%)

0 (0%)

0 (0%)

Fair

1 (20%)

0 (0%)

1 (10%)

Poor

0 (0%)

0 (0%)

0 (0%)

Very satisfied

3 (60%)

4 (80%)

7 (70%)

Satisfied

1 (20%)

1 (20%)

2 (20%)

Neutral

0 (0%)

0 (0%)

0 (0%)

Dissatisfied

1 (20%)

0 (0%)

1 (10%)

Very dissatisfied

0 (0%)

0 (0%)

0 (0%)

Would recommend study to others

4 (80%)

5 (100%)

9 (90%)

Program satisfaction

a

Scale 1–5: 1 = not at all useful, 5 = very useful.

b

Resistance arm only.

c

Scale 1–5: 1 = very uncomfortable, 5 = very comfortable.

d

Scale 1–5: 1 = very inconvenient, 5 = very convenient.

e

None answered too short or too long.

f

Scale 1–5: 1 = very challenging/very hard, 5 = very easy.

g

Scale 1–5: 1 = very difficult, 5 = very easy.

cancer (mHSPC) (NCT02730338).17 Both CHAMP and
INTERVAL-GAP4 have lengthy eligibility criteria; however, the latter expanded eligibility to include those with
disease progression. Participants with angina and hypertension are eligible with physician clearance, and efforts
are being made to support exemption requests if the patient is well-suited but fails to meet the select criteria. This
is important to increase generalizability of the findings.
Remotely monitored behavioral interventions are
gaining importance, especially in geographic areas where
travel-related barriers such as high traffic congestion
negatively impact participation, and we obtained meaningful feedback from participants to improve adherence
to these interventions. CHAMP required use of a Polar
HR monitor, the Polar app (or paper log), and web-based
surveys, and the participants’ high technological literacy may have contributed to the success of the program.
Future programs must consider the literacy level of the
target population to adapt study onboarding as needed.
Some participants still had intermittent trouble with the
technology, so additional support and resources must also
be available. Further tailoring of the weekly call with the
exercise specialist and bringing patients onsite during the
program for personalized training and evaluation may be
useful. Although there could have been differences with

the personnel employed at each local gym, the study was
not designed around gym staff and relied solely on the
study's exercise physiologist for the exercise prescription
and coaching, which limited the gym-related requirements and helped to ensure standardized feedback for all
intervention participants.
There were many competing priorities with the intervention, including personal travel, life events, symptom
progression, and cancer recurrence, which affected participants’ perception of difficulty of the exercise program.
Participants were happy with their local gym experience
with remote monitoring, which gave them flexibility and
required minimal travel. In future studies, the use of a
timer app for work rest ratios and provision of additional
feedback on progress during and at the end of the program
may increase participants’ success and study satisfaction.
The study eliminated cost barriers to exercise during the
study period, but did not solve the long-term need for access to facilities. Future iterations of these interventions
could involve long-term collaborations with gyms to provide free or low-cost gym memberships to cancer patients
and/or survivors, such as the Young Men's Christian
Association (YMCA or Y) programs. Providing a guide
and home exercise equipment could be feasible based
on patient feedback, though further study is required to

12
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assess the safety and feasibility of remote interventions
for metastatic patients in the home setting. Virtual, home-
based interventions would allow the exercise specialist
to supervise participants while completing their exercise
prescription and remove the need for a public gym; while
a remote monitoring format utilizing local gyms may improve access to equipment that may not be feasible to buy
for virtual, home-based interventions.
Two studies, both 12 weeks, intentionally enrolled
metastatic PC patients with bone metastases to supervised
resistance or multimodal exercise, and reported that exercise was safe and well-tolerated.9,10 Our study focused
on remote self-monitored aerobic or resistance exercise
and reported that exercise is safe and well-tolerated when
performed independently, with the weekly guidance of
an exercise specialist. More recent studies successfully
incorporated hybrid formats. Bourke et al. conducted a 3-
month randomized trial of a combined aerobic and resistance + diet program versus control in 100 men on ADT
for locally advanced (N = 80) or metastatic (N = 20) PC.18
The program was tapered with two supervised sessions
and one self-directed session in weeks 1–6 and one supervised session and two self-directed sessions in weeks 7–
12. Adherence was 94% for the supervised and 82% for the
independent exercise sessions during the 12 weeks, with
durability observed at 6 months in fatigue and exercise behavior.18 Utilizing hybrid or tapered approaches may be
more feasible, and may help to increase self-efficacy and
long-term exercise habits, after the study ends.
A few studies, like CHAMP, are also integrating activity
trackers, for participant use and feedback.19–21 Cadmus-
Bertram et al. enrolled 50 non-metastatic breast and colorectal cancer survivors to receive a survivorship care plan
+/− a 12-week multicomponent physical activity module
with the goal to increase moderate-to-vigorous physical activity (MVPA) to 150 min/week and daily steps to 10,000.19
The module included a Fitbit (that integrated physical
activity data into the electronic health record (EHR) for
clinician review) and customized email feedback from a
coach (4 times in 12 weeks). The study reported improved
physical and mental health, sleep, exercise self-efficacy,
MVPA (69 min/week vs. 20 min/week), and steps (average increase of +1470 vs. −398 steps) in intervention
versus control.19,22 Exercise integrations with the EHR
or a participant/coach portal, or the use of a physical activity app + website provide more opportunity, flexibility, and support for remote-based exercise interventions.
Furthermore, incorporating exercise specialists in remote-
based studies of advanced cancer patients with additional
comorbidities is warranted, would promote safe exercise,
and may be less costly to implement than fully supervised
programs incorporating exercise physiologists or trainers.
To our knowledge, no other study in cancer survivors has

used exercise specialists in a remote capacity to regularly
monitor remote exercise based on individual exercise
prescriptions except for the Active Surveillance Exercise
Clinical Trial (ASX) study, which is ongoing in localized
PC patients (NCT02435472).
These CHAMP results guided the addition of the
CHAMP remote exercise protocol to the INTERVAL-
GAP4 trial protocol and affiliated sites are poised to
launch this format at the end of 2021. With the addition
of the CHAMP remote intervention option, INTERVAL
participants can now choose remotely monitored exercise
as an alternative option to onsite supervised exercise. The
study is open at 18 sites (with an additional 4 pending) in 8
countries, and we expect that the addition of the CHAMP
remote exercise protocol, which will be fully implemented
as gyms reopen when safe (closed due to COVID-19), will
allow additional sites to join and increase enrollment
rates, especially in locations where travel time is a barrier.
There are several limitations to consider. The study
was terminated early, and therefore the sample size was
smaller than planned. Although we observed improvements in fitness over the intervention period, we recognize that baseline values were dissimilar across groups,
which occurred by chance due to the small sample size.
The study was designed to examine the primary outcomes
of feasibility, safety, and acceptability and was not powered to assess the effects of the fitness-related secondary
outcomes. The intervention was limited to 12 weeks in duration, and longer term studies like INTERVAL are needed
to evaluate whether the high adherence we observed can
be maintained over time. Providing long-term support
as patients progress may also have beneficial effects on
functional outcomes and QOL. Two thirds of patients in
the remote exercise program were stable, while the remainder were progressing clinically. Lastly, most patients
were White, married, and highly educated. Future studies evaluating the feasibility of remote exercise training in
populations with more racial/ethnic and socioeconomic
diversity are warranted.
In this pilot RCT, exercise completed with remote supervision by an EP was feasible, safe, and acceptable for
men with mCRPC. Based on our findings we provide direction and rationale for future studies to determine the
effect of exercise on treatment toxicity, cancer symptoms,
QOL, and clinical outcomes for people living with metastatic cancer.
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